JPRN-jRCT2080221566未知3 期
Phase III double-blind study of TAK-536CCB in patients with grade I or II essential hypertensio
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点开始时间: 2011年9月6日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Main inclusion criteria:
- •1. Grade I or II essential hypertension.
排除标准
- •Main exclusion criteria:
- •1.Secondary hypertension, grade III hypertension, or malignant hypertension
- •2.Heart disease, cerebrovascular disease, vascular disease, or advanced hypertensive retinopathy
- •3.Hyperkalemia,etc
研究者
相似试验
未知
3 期
Phase III long-term study of TAK-536CCB in patients with grade I or II essential hypertensioHypertensionJPRN-jRCT2080221586TAKEDA PHARMACEUTICAL COMPANY LTD.
未知
3 期
A phase III study of TAK-536 (long-term use study)Essential hypertensionJPRN-jRCT2080220837Takeda Pharmaceutical Company Limited360
未知
3 期
Phase 3 study of TAK-536 (confirmatory trial)Essential hypertensionJPRN-jRCT2080220734Takeda Pharmaceutical Company Limited630
未知
3 期
An open-label study of TAK-536 in patients with grade III hypertensioHypertensionJPRN-jRCT2080220836Takeda Pharmaceutical Company Limited
未知
1 期
A phase I clinical pharmacology study of TAK-233 in healthy subjectsHealthy adult female subjectsJPRN-jRCT2080222396TAKEDA PHARMACEUTICAL COMPANY LTD.24